secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269506
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives
--------------------------------------------------------------------------------

- Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.
- Cash and investments $25.2M as of Sept 30, 2025, down from $51.3M at Dec 31, 2024.
- R&D expenses fell to $2.8M from $17.9M; G&A expenses $4.1M vs $7.6M year-over-year.
- Company continues to explore strategic alternatives to maximize stockholder value; engaged Cantor Fitzgerald.
- Phase 1 data for ALS candidate ATH-1105 showed favorable safety, dose-proportional PK, and CNS penetration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/0001193125-25-269506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer